Antiobesity Global Market Report 2026

Anti-obesity drugs are medications used to reduce or manage a patient's weight. These drugs work by targeting one of the body's fundamental functions-weight control-either by influencing appetite or affecting calorie absorption. Maintaining a healthy diet and engaging in regular exercise remain the primary therapeutic strategies for individuals who are overweight or obese.

The primary categories of drugs used in anti-obesity treatment are those that act peripherally and those that act centrally. Anti-obesity medications with a peripheral mechanism aid in weight loss without affecting the brain or suppressing appetite. They inhibit pancreatic lipase and prevent the breakdown of fats in the gastrointestinal tract, reducing fat absorption through the intestines. These drugs are available as prescription medications (Rx) and over-the-counter (OTC) products and include a variety of options such as monotherapies and combination therapies.

Tariffs have increased the cost of imported APIs used in antiobesity drug manufacturing and formulation activities. These impacts are most pronounced in North America and Europe, where many metabolic drug producers rely on global api supply networks. Rising tariff related input costs have placed pressure on production economics and pricing strategies for weight management therapies. This has influenced procurement planning and market access decisions among pharmaceutical companies. However, tariffs are also encouraging domestic manufacturing of metabolic drugs, localized api production, and stronger regional pharmaceutical supply chains over the long term.

The antiobesity market research report is one of a series of new reports from The Business Research Company that provides antiobesity market statistics, including antiobesity industry global market size, regional shares, competitors with a antiobesity market share, detailed antiobesity market segments, market trends and opportunities, and any further data you may need to thrive in the antiobesity industry. This antiobesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiobesity market size has grown strongly in recent years. It will grow from $4.1 billion in 2025 to $4.47 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to rising global obesity rates, limited success of lifestyle-only interventions, availability of appetite suppressants, growing metabolic disorder burden, physician-led weight management.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $6.56 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing prevalence of diabetes and obesity, innovation in hormone-based drugs, expansion of reimbursement coverage, rising obesity awareness, demand for sustainable weight loss solutions. Major trends in the forecast period include rapid adoption of glp-1 based therapies, growing preference for prescription weight loss drugs, increasing use of combination antiobesity therapies, rising focus on long-term weight management, expansion of obesity treatment access.

The increasing prevalence of obesity is expected to drive the growth of the anti-obesity drugs market in the coming years. Obesity is a chronic metabolic disorder marked by excessive accumulation of body fat, which elevates the risk of severe health complications such as diabetes, cardiovascular diseases, osteoarthritis, and certain types of cancer. The rise in obesity prevalence is largely attributed to higher consumption of ultra-processed foods rich in sugars, unhealthy fats, and refined carbohydrates, along with sedentary lifestyles that limit physical activity. This increase in obesity cases is creating a greater demand for effective anti-obesity medical treatments, supportive weight management therapies, and long-term interventions to reduce associated health risks and improve patient outcomes. For example, in March 2024, the World Obesity Federation, a UK-based organization dedicated to obesity research and advocacy, projected that by 2035, 79% of adults and 88% of children with overweight and obesity will reside in low- and middle-income countries. Consequently, the rising prevalence of obesity is propelling the growth of the anti-obesity drugs market.

Major companies in the anti-obesity market are emphasizing product innovation and formulation, such as dual glucose-dependent insulinotropic peptide (GIP) receptor agonists, to offer more effective weight loss, enhanced metabolic outcomes, and improved tolerability. These therapies utilize synergistic mechanisms on appetite suppression, insulin sensitivity, and energy expenditure to provide superior efficacy compared to earlier-generation GLP-1-only treatments. For example, in December 2024, Eli Lilly, a US-based pharmaceutical company, obtained FDA approval for Zepbound (tirzepatide), making it the first and only prescription dual GIP/GLP-1 agonist approved for chronic weight management. Tirzepatide has shown strong weight-loss efficacy, with phase 3 trial participants achieving substantial reductions in body weight. With this new indication, Zepbound is expected to strengthen Lilly's leadership in the precision obesity therapy field, addressing the rising demand for long-acting, high-efficacy treatments.

In August 2023, Eli Lilly, a US-based pharmaceutical company, acquired Versanis Bio for an undisclosed amount. Through this acquisition, Eli Lilly intends to enhance its anti-obesity drug portfolio by incorporating Versanis Bio's innovative therapies that target metabolic and weight-management pathways, facilitating the development of next-generation treatments for obesity and related metabolic disorders. Versanis Bio, a US-based biotechnology company, focuses on the development of novel therapeutics for obesity and metabolic diseases and has a strong track record in preclinical and early clinical research.

Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiobesity Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiobesity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antiobesity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Peripherally Acting Anti-Obesity Drugs; Centrally Acting Anti-Obesity Drugs
• 2) By Type: Prescription Drugs (Rx); OTC Drugs
• 3) By Medication: Monotherapies; Polytherapies
• Subsegments:
• 1) By Peripherally Acting Anti-Obesity Drugs: Orlistat; Lorcaserin
• 2) By Centrally Acting Anti-Obesity Drugs: Phentermine; Topiramate; Naltrexone-Bupropion Combination; Liraglutide
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Eisai Co. Ltd.; Novo Nordisk A/S; Zafgen Inc.; Rhythm Pharmaceuticals Inc.; Zydus Cadila; Norgine B.V.; Vivus Inc.; Arena Pharmaceuticals Inc.; Orexigen Therapeutics Inc.; Eli Lilly and Company; Amgen Inc.; AstraZeneca PLC; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Gelesis Inc.; Sanofi S.A.; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Lupin Ltd.; Torrent Pharmaceuticals Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.